Literature DB >> 24059338

Logical design of medical chaperone for prion diseases.

Kazuo Kuwata1.   

Abstract

A strategy of logical drug design (LDD) and its application to prion diseases are reviewed. LDD is primarily based on the localizability of a hot spot which initiates structural instability in the target protein. It is also based on the regulability of the hot spot by small compounds, their designabilty by a computer, their organic synthesizability and the specificity of their functions once administered to the biological organisms. Unification of localizability, regulability, producibility and specificity is the central theme of LDD. Theoretical foundation of LDD based on quantum theories is initially outlined. The localizability using nuclear magnetic resonance (NMR), the regulability by a medical chaperone, the synthesizability, and the functional specificity accomplished thus far, are then described.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24059338     DOI: 10.2174/15680266113136660171

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  3 in total

1.  Acid-induced molten globule state of a prion protein: crucial role of Strand 1-Helix 1-Strand 2 segment.

Authors:  Ryo P Honda; Kei-Ichi Yamaguchi; Kazuo Kuwata
Journal:  J Biol Chem       Date:  2014-09-12       Impact factor: 5.157

2.  A Single Subcutaneous Injection of Cellulose Ethers Administered Long before Infection Confers Sustained Protection against Prion Diseases in Rodents.

Authors:  Kenta Teruya; Ayumi Oguma; Keiko Nishizawa; Maki Kawata; Yuji Sakasegawa; Hiroshi Kamitakahara; Katsumi Doh-Ura
Journal:  PLoS Pathog       Date:  2016-12-14       Impact factor: 6.823

3.  Effects of ligand binding on the stability of aldo-keto reductases: Implications for stabilizer or destabilizer chaperones.

Authors:  Aurangazeb Kabir; Ryo P Honda; Yuji O Kamatari; Satoshi Endo; Mayuko Fukuoka; Kazuo Kuwata
Journal:  Protein Sci       Date:  2016-09-19       Impact factor: 6.725

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.